Business
REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023
-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of
About this update from Regenxbio Inc.
[{"type":"text","content":"-Interim results from Phase II AAVIATE and ALTITUDE trials of dose level 3 cohorts with short-course prophylactic steroid eye drops resulted in zero cases of intraocular inflammation\n-Initial safety results from Cohort 1 of the AFFINITY DUCHENNE study support well-tolerated profile to date; initial efficacy data to be presented at World Muscle Society meeting in October\n-A new program in Duchenne with preclinical data using innovative science to produce near full-length wild-type dystrophin; expects to file IND to the FDA in the first half of 2025\n-Detailed updates will be presented at its Virtual Investor Day, today at 8:30 a.m. ET\nROCKVILLE, Md., July 11, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) will announce today new interim data from the Phase II AAVIATE® and ALTITUDE® trials of ABBV-RGX-314 suprachoroidal delivery in wet AMD and diabetic retinopathy (DR). The company will also provide a comprehensive Duchenne program overview including initial safety data for RGX-202 and a new exon 53 program.\nREGENXBIO will host a virtual Investor Day today at 8:30 a.m. ET to discuss these updates. The webcast and slides of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com.\n\"We continue to perform at a high level as we execute on our mission of improving lives through the curative potential of gene therapy,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"Today, we are pleased to share an update on REGENXBIO's pipeline of AAV-based gene therapies with a focus on our retinal and Duchenne programs. The safety and tolerability data presented today for the high-dose cohorts of our in-office wet AMD and DR programs is encouraging and further validate the potential of the suprachoroidal space for AAV delivery to treat chronic retinal diseases.\"\nMr. Mills continued, \"I am also thrilled to share an update on our Duchenne program, from our neuromuscular franchise, which includes progress on RGX-202 and our new exon-skipping program that we have initiated. We continue to develop highly differentiated, transformational treatments with an unwavering commitment to advance therapies designed to prevent ambulation loss and improve the quality of life in boys worldwide, regardless of age, who suffer from Duchenne.\"\n\"I believe we have a clear and defin...